This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5yc0
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yc0 OCA], [http://pdbe.org/5yc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yc0 RCSB], [http://www.ebi.ac.uk/pdbsum/5yc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yc0 ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yc0 OCA], [http://pdbe.org/5yc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yc0 RCSB], [http://www.ebi.ac.uk/pdbsum/5yc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yc0 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Enfuvirtide (T20) is the only viral fusion inhibitor approved for clinical use, but it has relatively weak anti-HIV activity and easily induces drug resistance. In succession to T20, T1249 has been designed as a 39-mer peptide composed of amino acid sequences derived from HIV-1, HIV-2, and simian immunodeficiency virus (SIV); however, its development has been suspended due to formulation difficulties. We recently developed a T20-based lipopeptide (LP-40) showing greatly improved pharmaceutical properties. Here, we generated a T1249-based lipopeptide, termed LP-46, by replacing its C-terminal tryptophan-rich sequence with fatty acid. As compared to T20, T1249, and LP-40, the truncated LP-46 (31-mer) had dramatically increased activities in inhibiting a large panel of HIV-1 subtypes, with IC50 values approaching low picomolar (pM) concentrations. Also, LP-46 was an exceptionally potent inhibitor against HIV-2, SIV, and T20-resistant variants, and it displayed obvious synergistic effects with LP-40. Furthermore, we showed that LP-46 had increased helical stability and binding affinity with the target site. The crystal structure of LP-46 in complex with a target surrogate revealed its critical binding motifs underlying the mechanism of action. Interestingly, it was found that the introduced pocket-binding domain (PBD) in LP-46 did not interact with the gp41 pocket as expected; instead, it adopted a mode similar to that of LP-40. Therefore, our studies have provided an exceptionally potent and broad fusion inhibitor for developing new anti-HIV drugs, which can also serve as a tool to exploit the mechanisms of viral fusion and inhibition. | ||
| + | |||
| + | Exceptional Potency and Structural Basis of a T1249-Derived Lipopeptide Fusion Inhibitor against HIV-1, HIV-2, and Simian Immunodeficiency Virus.,Zhu Y, Zhang X, Ding X, Chong H, Cui S, He J, Wang X, He Y J Biol Chem. 2018 Feb 7. pii: RA118.001729. doi: 10.1074/jbc.RA118.001729. PMID:29425101<ref>PMID:29425101</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 5yc0" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Revision as of 07:13, 28 February 2018
Crystal structure of LP-46/N44
| |||||||||||
